Consumer Biotech: The Value Chain Beneath the GLP-1 Boom | EP 234
GLP-1 drugs and the peptide supply chain behind them have grown like no other drug class, reaching 44 million users within five years. Equity analyst Joshua Samuel looks past innovators Eli Lilly and Novo Nordisk to the contract manufacturers and consumables underneath them. He explains why oral GLP-1 pills can need up to 10 times more drug substance than an injection, walks through building a 39-amino-acid peptide like a LEGO set, and lays out why a silica gel supplier with about 70% global market share does not screen as a healthcare company. The conversation lands on a simple idea: growth…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.